Humacyte Inc
NASDAQ:HUMA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Humacyte Inc
NASDAQ:HUMA
|
US |
|
U
|
Ultimate Games SA
WSE:ULG
|
PL |
|
PCI Biotech Holding ASA
OSE:PCIB
|
NO |
|
G
|
GuocoLand (Malaysia) Bhd
KLSE:GUOCO
|
MY |
|
U
|
Universal Biosensors Inc
ASX:UBI
|
AU |
|
I
|
Inflection Point Acquisition Corp II
NASDAQ:IPXX
|
US |
|
Decisive Dividend Corp
XTSX:DE
|
CA |
|
C
|
Companhia Energetica do Rio Grande do Norte Cosern
BOVESPA:CSRN6
|
BR |
|
J
|
Jinzai Food Group Co Ltd
SZSE:003000
|
CN |
|
FM Mattsson AB (publ)
STO:FMM B
|
SE |
|
R
|
Rimon Consulting & Management Services Ltd
TASE:RMON
|
IL |
|
N
|
Nouveau Global Ventures Ltd
BSE:531465
|
IN |
|
S
|
Suzhou YourBest New-type Materials Co Ltd
SZSE:301266
|
CN |
|
Mind Technology Inc
NASDAQ:MIND
|
US |
Income Statement
Earnings Waterfall
Humacyte Inc
Income Statement
Humacyte Inc
| Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||
| Interest Expense |
3
|
3
|
4
|
5
|
6
|
6
|
6
|
6
|
7
|
7
|
7
|
7
|
8
|
8
|
9
|
10
|
10
|
11
|
|
| Revenue |
2
N/A
|
1
-36%
|
1
+4%
|
1
+6%
|
2
+46%
|
2
-11%
|
2
-10%
|
1
-15%
|
0
-98%
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
1
N/A
|
1
+58%
|
2
+92%
|
|
| Gross Profit | |||||||||||||||||||
| Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(1)
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
+24%
|
1
+108%
|
|
| Operating Income | |||||||||||||||||||
| Operating Expenses |
(74)
|
(76)
|
(82)
|
(81)
|
(84)
|
(87)
|
(86)
|
(87)
|
(94)
|
(95)
|
(100)
|
(104)
|
(107)
|
(112)
|
(114)
|
(111)
|
(112)
|
(106)
|
|
| Selling, General & Administrative |
(16)
|
(18)
|
(21)
|
(22)
|
(22)
|
(23)
|
(23)
|
(22)
|
(23)
|
(23)
|
(23)
|
(24)
|
(23)
|
(24)
|
(26)
|
(29)
|
(31)
|
(31)
|
|
| Research & Development |
(58)
|
(58)
|
(61)
|
(63)
|
(63)
|
(65)
|
(63)
|
(64)
|
(70)
|
(71)
|
(77)
|
(81)
|
(84)
|
(88)
|
0
|
(62)
|
(60)
|
(55)
|
|
| Other Operating Expenses |
0
|
0
|
0
|
3
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(88)
|
(20)
|
(21)
|
(21)
|
|
| Operating Income |
(72)
N/A
|
(75)
-5%
|
(81)
-8%
|
(80)
+2%
|
(82)
-3%
|
(85)
-4%
|
(85)
+1%
|
(85)
-1%
|
(94)
-10%
|
(95)
-1%
|
(100)
-6%
|
(104)
-4%
|
(107)
-3%
|
(112)
-5%
|
(114)
-1%
|
(110)
+3%
|
(111)
-1%
|
(105)
+5%
|
|
| Pre-Tax Income | |||||||||||||||||||
| Interest Income Expense |
(3)
|
(3)
|
(4)
|
(5)
|
(5)
|
(5)
|
(4)
|
(2)
|
(1)
|
(1)
|
(1)
|
(2)
|
(3)
|
(3)
|
0
|
11
|
10
|
12
|
|
| Non-Reccuring Items |
3
|
3
|
3
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
(10)
|
56
|
59
|
116
|
124
|
76
|
59
|
6
|
5
|
(10)
|
(1)
|
(30)
|
(37)
|
(33)
|
21
|
41
|
55
|
|
| Pre-Tax Income |
(71)
N/A
|
(85)
-19%
|
(26)
+69%
|
(26)
+2%
|
28
N/A
|
34
+22%
|
(12)
N/A
|
(29)
-143%
|
(89)
-205%
|
(89)
-1%
|
(111)
-24%
|
(106)
+4%
|
(140)
-32%
|
(153)
-9%
|
(149)
+3%
|
(78)
+48%
|
(59)
+25%
|
(37)
+37%
|
|
| Net Income | |||||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(71)
|
(85)
|
(26)
|
(26)
|
28
|
34
|
(12)
|
(29)
|
(89)
|
(89)
|
(111)
|
(106)
|
(140)
|
(153)
|
(149)
|
(78)
|
(59)
|
(37)
|
|
| Net Income (Common) |
(71)
N/A
|
(85)
-19%
|
(26)
+69%
|
(26)
+2%
|
28
N/A
|
34
+22%
|
(12)
N/A
|
(29)
-143%
|
(89)
-205%
|
(89)
-1%
|
(111)
-24%
|
(106)
+4%
|
(140)
-32%
|
(153)
-9%
|
(149)
+3%
|
(78)
+48%
|
(59)
+25%
|
(37)
+37%
|
|
| EPS (Diluted) |
-0.7
N/A
|
-0.84
-20%
|
-0.26
+69%
|
-0.26
N/A
|
0.26
N/A
|
0.32
+23%
|
-0.12
N/A
|
-0.3
-150%
|
-0.87
-190%
|
-0.87
N/A
|
-1.07
-23%
|
-0.97
+9%
|
-1.17
-21%
|
-1.28
-9%
|
-1.26
+2%
|
-0.59
+53%
|
-0.37
+37%
|
-0.22
+41%
|
|